NCT03853317Phase 2Terminated

QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2021-09-29Actual

Enrollment · participants9Actual

Source updated2024-08-09Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Merkel Cell Carcinoma

Treatments or interventions studied

AvelumabBiologicalAlso known as (BAVENCIO® injection, for intravenous [IV] use)
N-803BiologicalAlso known as also known as IL-15N72D:IL-15RαSu/IgG1 Fc complex]), ALT-803
haNK™BiologicalAlso known as NK-92 [CD16.158V, ER IL-2], (haNK™ for Infusion)

Primary outcomes · main study measures

Read the study measures

measure: Number of Participants With Adverse Events; description: The safety of the combination treatment of avelumab, haNK, and N-803 in subjects with MCC that has progressed on or after checkpoint inhibitor therapy; timeFrame: 30 days after last dose, approximately 1 year 7 months; measure: Objective Response Rate; description: Percent of subjects with confirmed complete Response (CR; disappearance of all target lesions) or partial response (PR; \>=30% decrease in the sum of the longest diameter of target lesions) by RECIST v1.1; timeFrame: approximately 1 year 7 months

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history